Eyeworld

EW IN OTHER NEWS 78 July 2018 throughout the year where they test new tires or technology. Before every race, there is also typically a test day where there are four to five sessions of 10–20 minutes, which is where Dr. Sohn can get a feel for the car again and the conditions of the track, which allows him to determine if there are any changes he needs to make before the qualifi- cation round and the actual race. With the Institute for Vision Research logo on his car and the tagline "Racing to Cure Blindness" on his social media accounts, Dr. Sohn plans to participate in five races during his 2018 racing season and hopes to make it to the SCCA National Championship Runoffs, which are being held in October in Sonoma, California, again. "I want to place first in some races this year," he said. "I hope people come out to the races and hear about some of the work we're doing at the University of Iowa in terms of vision research." There is a lot of overlap between racing and ophthalmology when it comes to mental focus, reflexes, and dexterity, Dr. Sohn said. "The mentality of trying to do the very best that you can and learn from every single encounter, every single experience is something that translates well between racing and other experiences in life," Dr. Sohn said. "Every time you take a turn, the speed that you enter the corner and the speed you come out of the corner, when you turn in, when you brake, when you come off the brake—all of those things can be the difference between first place and second place. Trying to analyze those things in a way where you can change them and make them better is something I'm trying to apply to my life as an academic physician, whether it's trying to write a paper better, a grant better, trying to teach residents and fellows better, trying to discover something or make a process more efficient. I think there are a lot of similarities between rac- ing and academic ophthalmology in that aspect, too," Dr. Sohn said. EW Reference 1. Smithsonian National Air and Space Museum. How Things Fly. howthingsfly. si.edu/ask-an-explainer/what-mini- mum-speed-needed-airplane-runway-takeoff. Accessed March 28, 2018. Contact information Sohn: fb.com/sohnracing "It was the first time in the or- ganization's history that the runoff had ever been held there. It's a spe- cial place that the vast majority of racers don't get access to, so it was extremely special to be there for 10 days and be on track for 6 of those 10," Dr. Sohn said. Unfortunately, Dr. Sohn said his finish was disappointing as he came down with a flat tire in the second lap. "Once the tire is changed, you've been out for several minutes of that race, and the race is only 30 minutes long," Dr. Sohn said. There are a lot of factors that add up to a good finishing time. "Your crew makes a huge dif- ference in terms of how you do in a race. The driver, no doubt, is the biggest variable, but little things like tires and other things on the car, if they go bad, can take you out of a race," Dr. Sohn said. During the off season or between races, Dr. Sohn practices us- ing a virtual reality system, race-sim- ulation seat, force-feedback wheel, and the iRacing simulator where he races against others virtually and in real time. "It's kind of like doing eye sur- gery where you can watch videos of doing surgery, you can hear lectures about it, you can read books about it, but there is nothing that replaces actually doing it," Dr. Sohn said, explaining that the virtual reality system at least allows him to prepare mentally. "A beautiful thing about it is you can learn tracks you haven't been to before you actually race on them. You can also learn some art forms in racing that are difficult to get without actually racing, such as the art of passing." He also found increasing his physical fitness regimen upped his racing abilities. "I remember the first time I was in the race car that I bought last year," Dr. Sohn said. "My whole body was sore—my back muscles, my arms, one of my legs, I had soreness in my thumbs because of the way you grip the steering wheel. Even though I had done some stuff to keep physically fit before, I upped my workouts after I started racing. I noticed that my physical fitness played a role in trying to handle a 20- to 30-minute session where you are pushing yourself. You have to be in complete mental focus, you have to get your body to do exactly what your mind wants. Having good reflexes, strength, and endurance plays a role in that." Dr. Sohn said he and his team will do a couple of test sessions not get passed yourself," Dr. Sohn explained. "On those straights, at first, I was thinking, 'Wow, this is really fast. My helmet is coming off because of the drag.' But now on those same straightaways, it's more like it's time to relax. I'm relaxing my hands, relaxing my body, and thinking about how I am going to do the next lap better, the next set of turns better." Out of the races he did last year (five to six weekends where there are usually two races per weekend event), Dr. Sohn said he was able to "get podium," or place within the top three, in three races. One of those was a SCCA Majors race, which he said generally attracts more intense competition. Getting to Indianapolis for the SCCA National Championship Run- offs was his goal last year. Racing continued from page 76 © 2018 Novartis 2/18 US-CYP-18-E-0312 CYPASS ® ULTRA SYSTEM IMPORTANT PRODUCT INFORMATION CAUTION: FEDERAL (USA) LAW RESTRICTS THIS DEVICE TO SALE BY OR ON THE ORDER OF A PHYSICIAN. INDICATION: The CYPASS ® Ultra System is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG). CONTRAINDICATIONS: Use of the CYPASS ® Ultra System is contraindicated in the following circumstances or conditions: (1) in eyes with angle closure glaucoma; and (2) in eyes with traumatic, malignant, uveitic or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle. MRI INFORMATION: The CYPASS ® Micro-Stent is magnetic resonance (MR) Safe: the implant is constructed of polyimide material, a non-conducting, non-metallic, non-magnetic polymer that poses no known hazards in all magnetic resonance imaging environments. WARNINGS: Gonioscopy should be performed prior to surgery to exclude peripheral anterior synechiae (PAS), rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. PRECAUTIONS: The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the CYPASS ® Ultra System has not been established as an alternative to the primary treatment of glaucoma with medications, in patients 21 years or younger, in eyes with significant prior trauma, chronic inflammation, eyes with an abnormal anterior segment, eyes with chronic inflammation, eyes with glaucoma associated with vascular disorders, pseudophakic eyes with glaucoma, eyes with uveitic glaucoma, eyes with pseudoexfoliative or pigmentary glaucoma, eyes with other secondary open angle glaucomas, eyes that have undergone prior incisional glaucoma surgery or cilioablative procedures, eyes with laser trabeculoplasty performed ≤ 3 months prior to the surgical screening visit, eyes with unmedicated IOP less than 21 mmHg or greater than 33 mmHg, eyes with medicated IOP greater than 25 mmHg, in the setting of complicated cataract surgery with iatrogenic injury to the anterior or posterior segment, and when implantation is without concomitant cataract surgery with IOL implantation for visually significant cataract. The safety and effectiveness of use of more than a single CYPASS ® Micro-Stent has not been established. ADVERSE EVENTS: In a randomized, multicenter clinical trial comparing cataract surgery with the CYPASS ® Micro-Stent to cataract surgery alone, the most common post-operative adverse events included: BCVA loss of 10 or more letters at 3 months after surgery (8.8% for CYPASS ® vs. 15.3% for cataract surgery only); anterior chamber cell and flare requiring steroid treatment 30 or more days after surgery (8.6% vs. 3.8%); worsening of visual field mean deviation by 2.5 or more decibels (6.7% vs. 9.9%); IOP increase of 10 or more mmHg 30 or more days after surgery (4.3% vs. 2.3%); and corneal edema 30 or more days after surgery, or severe in nature (3.5% vs. 1.5%). ATTENTION: PLEASE REFER TO THE PRODUCT INSTRUCTIONS FOR A COMPLETE LIST OF CONTRAINDICATIONS, WARNINGS, PRECAUTIONS AND ADVERSE EVENTS. 101881 US-CYP-18-E-0312_PI EW.indd 1 6/12/18 9:10 AM

• Blank Page
• Blank Page (1)